|
|
|
Volumn 17, Issue 8, 2009, Pages 569-573
|
|
[Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIFUNGAL AGENT;
HEPATITIS B(E) ANTIGEN;
LAMIVUDINE;
NUCLEOSIDE;
PRESCRIPTION DRUG;
PYRIMIDINONE DERIVATIVE;
TELBIVUDINE;
VIRUS DNA;
ADULT;
ARTICLE;
BLOOD;
CHINA;
COMPARATIVE STUDY;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
EVALUATION;
FEMALE;
HEALTH INSURANCE;
HEPATITIS B;
HUMAN;
LIVER CIRRHOSIS;
MALE;
MIDDLE AGED;
PHARMACOECONOMICS;
PROBABILITY;
QUALITY ADJUSTED LIFE YEAR;
STATISTICAL MODEL;
STATISTICS;
ADULT;
ANTIFUNGAL AGENTS;
CHINA;
COST-BENEFIT ANALYSIS;
DNA, VIRAL;
DRUG COSTS;
ECONOMICS, PHARMACEUTICAL;
FEMALE;
HEPATITIS B E ANTIGENS;
HEPATITIS B, CHRONIC;
HUMANS;
INSURANCE, LONG-TERM CARE;
LAMIVUDINE;
LIVER CIRRHOSIS;
MALE;
MARKOV CHAINS;
MIDDLE AGED;
MODELS, ECONOMIC;
NUCLEOSIDES;
PRESCRIPTION DRUGS;
PYRIMIDINONES;
QUALITY-ADJUSTED LIFE YEARS;
|
|
EID: 77953663211
PISSN: 10073418
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
